We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.

I Agree

You are here: Industry Insights > VAZALORE

News List

PLx Pharma Receives FDA Approval of SNDAs for Two VAZALORE Dosages americanpharmaceuticalreview
March 04, 2021
PLx Pharma announced the U.S. Food and Drug Administration (FDA) approved supplemental new drug applications (sNDAs) for its lead products, VAZALORE™ 325 mg and VAZALORE™ 81 mg (referred to together as VAZALORE), the first novel, liquid-filled aspirin ...
PLx Pharma Submits sNDAs for VAZALORE americanpharmaceuticalreview
November 26, 2020
PLx Pharma announced two chemistry and manufacturing control (CMC) supplemental New Drug Applications (sNDAs), one for VAZALORE 325 mg and one for VAZALORE 81 mg dose (referred to together as VAZALORE), have been submitted to the U.S. Food and Drug ...